Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his ...
The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...
The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.
The drama continued Monday with senior FDA leaders as more details emerged about former Center for Drug Evaluation and ...
Developers of biosimilars will no longer be required by the FDA to conduct clinical trials to prove effectiveness.
The FDA is expected to decide on treatments for asthma, chronic rhinosinusitis with nasal polyps, dyslipidemia, Cushing syndrome, gonorrhea, HSCT-associated thrombotic microangiopathy, marginal zone ...
The U.S. FDA once again has a leadership gap at the top of its drug center, which already has been ravaged this year by massive terminations, resignations and retirements of senior leaders. George ...
Through our Venable FDA Pulse series, we provide insight into key developments within the Food and Drug Administration (FDA or the Agency), ...
Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent ...
Green Matters on MSN
FDA Recalls More Than 140,000 Bottles of Cholesterol Medications Due to High Health Risk They Pose
Massive recall of 141,984 bottles of Cholesterol medicine gets an update. In September, the Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback